Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > IL23A & IL12B

IL23A & IL12B

Brief Information

Name:Interleukin-23
Target Synonym:Interleukin-23
Number of Launched Drugs:3
Number of Drugs in Clinical Trials:17
Lastest Research Phase:Approved

Product ListCompare or Buy

ACRO Quality

Part of Bioactivity data

ILB-H82W6-Cell-based assay
 IL23A & IL12B CELL

Biotinylated Human IL-23A&IL-12B Heterodimer Protein, His,Avitag&Tag Free (Cat. No. ILB-H82W6) stimulates secretion of IL-17 by mousespleen cells. The ED50 for this effect is 0.191-0.2173 ng/mL (Routinely tested).

ILB-H82W6-Cell-based assay
 IL23A & IL12B CELL

Cell based assay shows that the secretion of IL-17 induced by Biotinylated Human IL-23A&IL-12B Heterodimer Protein, His,Avitag&Tag Free (Cat. No. ILB-H82W6) is inhibited by increasing concentration of the anti-human IL-23 neutralizing antibody. The IC50 is between 0.25-1.40 ng/mL (Routinely tested).

ILB-H82W6-SPR
 IL23A & IL12B SPR

Captured Biotinylated Human IL-23A&IL-12B Heterodimer Protein, His,Avitag&Tag Free (Cat. No. ILB-H82W6) on Biotin CAP - Series S sensor Chip can bind Human IL-23 R, His Tag (Cat. No. ILR-H52H4) affinity constant of 4.77 nM as determined in a SPR assay (Biacore T200) (Routinely tested).

ILB-H52W5-SPR
 IL23A & IL12B SPR

Captured Human IL-23 R, Fc Tag (Cat. No. ILR-H5254) on CM5 chip via anti-human IgG Fc antibodies surface can bind Human IL-23A&IL-12B Heterodimer Protein, His Tag&Tag Free (Cat. No. ILB-H52W5) with an affinity constant of 5.36 nM as determined in a SPR assay (Biacore T200) (Routinely tested).

IL23A & IL12B Molecule Synonym Name

IL-23 alpha & IL-12 beta

IL23A & IL12B Molecule Background

Interleukin-23 subunit alpha (IL-23 alpha) can associates with IL12B to form the IL-23 interleukin, a heterodimeric cytokine which functions in innate and adaptive immunity. IL-23 may constitute with IL-17 an acute response to infection in peripheral tissues. IL-23 binds to a heterodimeric receptor complex composed of IL12RB1 and IL23R, activates the Jak-Stat signaling cascade, stimulates memory rather than naive T-cells and promotes production of proinflammatory cytokines. IL-23 induces autoimmune inflammation and thus may be responsible for autoimmune inflammatory diseases and may be important for tumorigenesis.

IL23A & IL12B References

Related Molecule

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Ustekinumab CNTO-1275; C-340 Approved Johnson & Johnson Innovative Medicine Stelara, 喜达诺 United States Plaque psoriasis Janssen Biotech Inc 2009-09-25 Arthritis, Juvenile; Crohn Disease; Dermatitis, Atopic; Plaque psoriasis; Hidradenitis Suppurativa; Uveitis; Common Variable Immunodeficiency; Colitis, Ulcerative; Arthritis, Psoriatic; Takayasu Arteritis; Psoriasis; Lupus Erythematosus, Systemic; Liver Cirrhosis, Biliary; Multiple Sclerosis; Sjogren's Syndrome; Pouchitis; Ichthyosis; Inflammatory Bowel Diseases; Type I Leukocyte Adhesion Defect; Dermatomyositis; Non-radiographic axial spondyloarthritis; Diabetes Mellitus, Type 1; Polymyositis Details
Ustekinumab biosimilar (Alvotech) AVT04; AVT-04 Approved Alvotech hf Jamteki, Uzpruvo, SELARSDI™ Japan Psoriasis Fuji Pharma Co Ltd 2023-09-25 Psoriasis; Arthritis, Psoriatic; Plaque psoriasis; Crohn Disease Details
Ustekinumab biosimilar(Amgen) ABP-654 Approved Amgen Inc Wezlana, WEZLANA United States Crohn Disease; Plaque psoriasis; Arthritis, Psoriatic; Colitis, Ulcerative Amgen Inc 2023-10-31 Psoriasis; Arthritis, Psoriatic; Colitis, Ulcerative; Crohn Disease; Plaque psoriasis Details
Ustekinumab CNTO-1275; C-340 Approved Johnson & Johnson Innovative Medicine Stelara, 喜达诺 United States Plaque psoriasis Janssen Biotech Inc 2009-09-25 Arthritis, Juvenile; Crohn Disease; Dermatitis, Atopic; Plaque psoriasis; Hidradenitis Suppurativa; Uveitis; Common Variable Immunodeficiency; Colitis, Ulcerative; Arthritis, Psoriatic; Takayasu Arteritis; Psoriasis; Lupus Erythematosus, Systemic; Liver Cirrhosis, Biliary; Multiple Sclerosis; Sjogren's Syndrome; Pouchitis; Ichthyosis; Inflammatory Bowel Diseases; Type I Leukocyte Adhesion Defect; Dermatomyositis; Non-radiographic axial spondyloarthritis; Diabetes Mellitus, Type 1; Polymyositis Details
Ustekinumab biosimilar (Alvotech) AVT04; AVT-04 Approved Alvotech hf Jamteki, Uzpruvo, SELARSDI™ Japan Psoriasis Fuji Pharma Co Ltd 2023-09-25 Psoriasis; Arthritis, Psoriatic; Plaque psoriasis; Crohn Disease Details
Ustekinumab biosimilar(Amgen) ABP-654 Approved Amgen Inc Wezlana, WEZLANA United States Crohn Disease; Plaque psoriasis; Arthritis, Psoriatic; Colitis, Ulcerative Amgen Inc 2023-10-31 Psoriasis; Arthritis, Psoriatic; Colitis, Ulcerative; Crohn Disease; Plaque psoriasis Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Ustekinumab biosimilar(Formycon) FYB-202 Phase 3 Clinical Formycon Psoriasis Details
Ustekinumab Biosimilar (qyuns) QX-001-S; HDM-3001; QX-001S Phase 3 Clinical Qyuns Therapeutics Co Ltd Psoriasis; Plaque psoriasis Details
Ustekinumab Biosimilar(Celltrion) CT-P43 Phase 3 Clinical Celltrion Inc Psoriasis Details
Ustekinumab biosimilar(Biocon) Phase 3 Clinical Biocon Biologics Ltd Psoriasis Details
Ustekinumab biosimilar(CSPC Pharma) SYSA-1902 Phase 3 Clinical Jushi Biopharmaceutical Co Ltd Psoriasis; Plaque psoriasis Details
Brazikumab AMG-139; MEDI-2070; Anti-IL-23-MAb (Amgen) Phase 2 Clinical Amgen Inc Inflammatory Bowel Diseases; Psoriasis; Colitis, Ulcerative; Crohn Disease Details
anti-cancer mRNA therapeutics (Moderna Therapeutics) mRNA-2752 Phase 1 Clinical Moderna Inc, Astrazeneca Plc Solid tumours; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms; Neoplasms; Carcinoma, Transitional Cell; Lymphoma; Lymphoma, Non-Hodgkin; Carcinoma, Non-Small-Cell Lung; Melanoma Details
LY-900021 LY-900021 Phase 1 Clinical Halozyme Therapeutics Inc, Eli Lilly And Company Details
IL-23/CGRP bispecific antibody (Lilly) Phase 1 Clinical Eli Lilly And Company Autoimmune Diseases Details
Ustekinumab Biosimilar (NeuClone/Serum Institute of India) Phase 1 Clinical Neuclone, Serum Institute Of India Ltd Autoimmune Diseases Details
Ustekinumab biosimilar(Rani Therapeutics) RT-111 Phase 1 Clinical Rani Therapeutics Llc Psoriasis Details
SOR-102 SOR-102 Phase 1 Clinical Sorriso Pharmaceuticals Inc Inflammatory Bowel Diseases; Colitis, Ulcerative Details
Ustekinumab biosimilar (BioFactura) BFI-751 Phase 1 Clinical BioFactura Australia Pty Ltd Psoriasis Details
Kagocel Clinical Nearmedic Plus Llc Respiratory Tract Infections; Respirovirus Infections; Influenza, Human Details
Ustekinumab biosimilar(Formycon) FYB-202 Phase 3 Clinical Formycon Psoriasis Details
Ustekinumab Biosimilar (qyuns) QX-001-S; HDM-3001; QX-001S Phase 3 Clinical Qyuns Therapeutics Co Ltd Psoriasis; Plaque psoriasis Details
Ustekinumab Biosimilar(Celltrion) CT-P43 Phase 3 Clinical Celltrion Inc Psoriasis Details
Ustekinumab biosimilar(Biocon) Phase 3 Clinical Biocon Biologics Ltd Psoriasis Details
Ustekinumab biosimilar(CSPC Pharma) SYSA-1902 Phase 3 Clinical Jushi Biopharmaceutical Co Ltd Psoriasis; Plaque psoriasis Details
Brazikumab AMG-139; MEDI-2070; Anti-IL-23-MAb (Amgen) Phase 2 Clinical Amgen Inc Inflammatory Bowel Diseases; Psoriasis; Colitis, Ulcerative; Crohn Disease Details
anti-cancer mRNA therapeutics (Moderna Therapeutics) mRNA-2752 Phase 1 Clinical Moderna Inc, Astrazeneca Plc Solid tumours; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms; Neoplasms; Carcinoma, Transitional Cell; Lymphoma; Lymphoma, Non-Hodgkin; Carcinoma, Non-Small-Cell Lung; Melanoma Details
LY-900021 LY-900021 Phase 1 Clinical Halozyme Therapeutics Inc, Eli Lilly And Company Details
IL-23/CGRP bispecific antibody (Lilly) Phase 1 Clinical Eli Lilly And Company Autoimmune Diseases Details
Ustekinumab Biosimilar (NeuClone/Serum Institute of India) Phase 1 Clinical Neuclone, Serum Institute Of India Ltd Autoimmune Diseases Details
Ustekinumab biosimilar(Rani Therapeutics) RT-111 Phase 1 Clinical Rani Therapeutics Llc Psoriasis Details
SOR-102 SOR-102 Phase 1 Clinical Sorriso Pharmaceuticals Inc Inflammatory Bowel Diseases; Colitis, Ulcerative Details
Ustekinumab biosimilar (BioFactura) BFI-751 Phase 1 Clinical BioFactura Australia Pty Ltd Psoriasis Details
Kagocel Clinical Nearmedic Plus Llc Respiratory Tract Infections; Respirovirus Infections; Influenza, Human Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message